Skin cell proliferation pathway

"Skin cell proliferation pathway" is not a specific molecule, receptor, or canonical therapeutic target. Instead, it refers to a collection of molecular signaling pathways that regulate the growth and division of skin cells (keratinocytes) during normal development, wound healing, and disease states such as cancer. Key pathways involved include Wnt, Hedgehog (SHH), TGF-beta, NF-kappaB, Ras/MAPK/EGFR/AP1 signaling cascades[1][2]. These pathways collectively control processes like epidermal specification, stratification, differentiation, and response to stress or injury. Dysregulation of these pathways is implicated in various skin cancers—including basal cell carcinoma and squamous cell carcinoma—where distinct subtypes may show enrichment for different pathway activities[1][2]. > The term "skin cell proliferation pathway" is too broad for use as a canonical drug target; instead, individual components within these pathways (such as specific receptors or kinases) are considered valid therapeutic targets. Note on correctness: This entry does not correspond to a single molecule or receptor but rather describes an entire set of biological processes/pathways. Therefore: - It should not be treated as a canonical drug target. - There is no standard abbreviation or alias. - No direct drugs interact with "the pathway" itself; drugs typically act on individual proteins within these networks. If you need structured information about specific molecules within the skin cell proliferation pathway—such as Epidermal Growth Factor Receptor (EGFR), Hedgehog protein (SHH), etc.—please specify the exact protein/receptor name for accurate data extraction[1][2].